Table 3. Long-term follow-up data with BRAF inhibitors.
| Agents | OS rate (%) |
|---|---|
| BRIM-1 study | 6 months: 87.3; 1 year: 55.0; 2 years: 35.6; 3 years: 25.9 |
| BRIM-3 study | 1 year: 56 |
| BREAK-2 study | 18.8 months V600K: 25; 30 months V600E: 28 |
| BREAK-3 study | 2 years: 45 |
OS, overall survival.